PON1 and triple-A syndrome: In line with these findings, we previously demonstrated that the injection of an apoA-I mimetic peptide (D4F) and overexpression of the main anti-inflammatory/antioxidant HDL enzyme paraoxonase (PON) 1 inhibited experimental AAA progression [16,26].